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Type 2 diabetes mellitusAbstract Background and aim of work: Persistent oxidative stress is one of several factors that
participate in the pathogenesis of type 2 diabetes mellitus (T2DM). Glutathione S-transferases
(GSTs) are a family of antioxidant enzymes that exert important antioxidant roles in the elimina-
tion of reactive oxygen species. We aimed to assess the association of genetic polymorphisms in the
GST isoenzymes M1, T1 and P1 with the risk of developing T2DM and its vascular related com-
plications in Egyptian diabetic patients.
Subjects and methods: Fifty-four T2DM patients of whom twenty-seven were suffering from vas-
cular complications were compared to ﬁfty-one healthy volunteers. Null genotypes in the GST
M1 and T1 genes were screened using polymerase chain reaction (PCR). The A313G single nucle-
otide polymorphism in the GSTP1 gene was detected using PCR–restriction fragment length
polymorphism.
Results: No signiﬁcant differences were noted between diabetic cases and control group regarding
frequencies of null genotypes of GSTM1 and GSTT1 genes (v2p= 0.631 and v2p= 0.832, respec-
tively). Furthermore, both null genotypes were not associated with the risk of developing T2DM
or its related vascular complications whether alone or in combination. The frequency of the
74 M.A. Zaki et al.heterozygous mutation (AG) in the A313G GSTP1 polymorphism among diabetic cases with and
diabetic cases without vascular complications was signiﬁcantly higher compared to the control
group (p= 0.023). The risk of developing T2DM was signiﬁcantly higher in cases presenting with
combined heterozygous GSTP1 and null GSTM1 genotypes (Odds ratio = 6.285, 95% conﬁdence
interval = 1.184–33.347, p= 0.021).
Conclusion: Our results could point out to potential roles of GSTP1 polymorphism alone or com-
bined with GSTM1 gene polymorphism in the pathogenesis of T2DM related oxidative stress.
Screening for other functional GST gene polymorphisms is important to understand the impact
of interaction of multiple genetic factors in the pathogenesis of T2DM.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Diabetes mellitus (DM) represents a group of metabolic
diseases characterized by hyperglycemia resulting from
defects in pancreatic insulin secretion, insulin action, or
both. The chronic hyperglycemia of diabetes is associated
with long-term damage, dysfunction, and failure of different
organs, especially the eyes, kidneys, nerves, heart, and
blood vessels.1 Diabetes remains a major public health
issue. In 2010, it was estimated that 4.787 million Egyptians
suffer from diabetes, particularly type 2 (T2DM), and that
diabetes will increase to 8.615 million Egyptians by the year
2030.2,3
Oxidative stress is one of several mechanisms that contrib-
ute in the pathogenesis of T2DM and its related vascular com-
plications. It represents a state of imbalance between pro-
oxidants and antioxidant defense system. The hyperglycemia
induced overproduction of reactive oxygen species (ROS) such
as superoxide, hydrogen peroxide and hydroxyl radical, along
with reactive nitrogen species (RNS) such as nitric oxide causes
oxidation of DNA, proteins and other cellular components
leading to their damage.4,5 The metabolic abnormalities of dia-
betes cause increased mitochondrial superoxide overproduc-
tion in endothelial cells of both large and small vessels, as
well as the myocardium. This causes the activation of major
pathways which increase intracellular ROS.6,7
Studies have shown that individuals with lowered
antioxidant capacity are at increased risk of T2DM.8,9
Alterations in the endogenous ROS scavenging defense mecha-
nisms may lead to ineffective scavenging of ROS, resulting in
oxidative damage and tissue injury.3 Pancreatic b-cells have
emerged as a putative target of oxidative stress-induced tissue
damage being sensitive to cytotoxic stress because of their little
expression of antioxidant enzymes. This seems to explain in
part the progressive deterioration of b-cell function in T2DM.10
Different families have been identiﬁed in detoxiﬁcation or
reduction of ROS production. Glutathione S-transferases
(GSTs) are the most important family of phase II isoenzymes
known to detoxify a variety of electrophilic compounds,
including carcinogens, chemotherapeutic drugs, environmental
toxins, and DNA products generated by ROS damage to intra-
cellular molecules. Detoxiﬁcation via GSTs is achieved by con-
jugating them with glutathione. GSTs thus play a major role as
cellular antimutagen and in antioxidant defense mechanisms.11
Two distinct superfamilies of GST isoenzymes exist; one fam-
ily comprises cytosolic, soluble dimeric enzymes,12 and the
other superfamily is composed of membrane bound trimericproteins named the membrane associated proteins in eicosa-
noid and glutathione (MAPEG) metabolism.13
Human soluble GSTs collectively account for 4% of total
soluble proteins in the liver. They exist as 50 KDa dimeric pro-
teins with both subunits being from the same class of GSTs.14
Based on sequence similarity, at least eight members of the
cytosolic family have been identiﬁed in humans named Mu
(M), Kappa (K), Alpha (A), Pi (P), Omega (O), Theta (T),
Zeta (Z), and Sigma (S).15
Among candidate genes related to oxidative stress, genes
for cytosolic GSTs, particularly GSTM1, GSTT1 and GSTP1
were intensively studied in different disease states owing to
their potential modulating roles in individual susceptibility to
environmentally induced diseases. GSTM1 and GSTT1 genes
are polymorphic in humans and the null genotypes are accom-
panied by lack of enzyme activity.16,17 On the other hand, the
GSTP1 single nucleotide polymorphism (SNP) present on
exon 5 is characterized by guanine replacing adenine base at
position 313 (A313G) of the gene nucleotides. This results in
valine replacing isoleucine amino acid at position 105 in the
GSTP1 isoenzyme protein. Such replacement results in the
appearance of a new allele with alteration in speciﬁc activity
for substrate compared to wild-type allele.18
Several investigators have determined the clinical or genetic
factors associated with T2DM with interests to detoxiﬁcation
agents. As regards GSTM1, T1 and P1 isoenzymes, studies
on Egyptian,3 Chinese,19 and Brazilian20 populations reported
a signiﬁcant association of the null mutation of GSTT1 gene
and T2DM, whereas in studies involving Turkish,21,22 North
Indian,23 and Southern Iran24 populations this association
was observed between GSTM1 deletion and T2DM. Recently,
studies conducted on Japanese25 and South Indian popula-
tion26 as well as another meta-analysis study involving Asian,
European and African diabetic populations27 reported the
association of both GSTM1 and GSTT1 null genotypes with
the risk of developing T2DM. The North Indian23 and another
Egyptian study conducted in T2DM28 were the only ones dem-
onstrating a signiﬁcant association of the GSTP1 SNP
(A313G) with T2DM.
The different ethnic backgrounds creating such a contro-
versy in results and scarcity of GST genetic studies conducted
among Egyptian T2DM patients invited us to carry out this
case-control study to assess the frequency of GSTM1, GSTT1
and GSTP1 genotypes in T2DM and explore any possible
relation(s) between the genotypes and the risk of developing
T2DM and its related vascular complications. To the best
of our knowledge, the current study is one of few studies address-
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GSTT1 gene polymorphisms among Egyptian T2DM patients.
2. Subjects
Informed consents were obtained from the one hundred and ﬁve
individuals enrolled in this study. The Research Ethics Commit-
tee of theMedical Research Institute approved the study proto-
col. Fifty-four diabetic patients were selected from the Internal
Medicine department of the Institute, with twenty-seven of them
suffering fromT2DMrelated vascular complications at the time
of the study. Fifty-one apparently healthy volunteers obtained
from the outpatient clinics of the Institute served as a control
group. Cases suffering from any type of malignancy as well as
bronchial asthma, hypertension preceding T2DM, cardiac, pri-
mary renal and liver diseases were excluded from this study.3. Methods
3.1. Clinical examination and anthropometric measurements
To all the studied subjects, a thorough history was taken
with stress on the duration of diabetes, as well as T2DM
related vascular complications. Physical examination was
done with stress on diabetes related vascular complications.
Blood pressure was recorded. Ultrasonographic evaluation
of the liver and kidneys was done. A slit lamp fundus exam-
ination to document retinopathy and a 12 lead standard
electrocardiogram to document diabetic ischemic changes
were done. Anthropometric measurements, namely body
weight and height along with the calculation of body mass
index (BMI) were done. Ultrasonographic determination of
the right and left carotid arteries intima media thickness
(CIMT) was done using a b-mode ultrasound to detect
peripheral atherosclerotic changes.29
3.2. Laboratory investigations
3.2.1. Biochemical analysis
Following a twelve hour fasting period, concomitant venous
blood samples and early morning midstream urine speci-
mens were obtained from every participant. Fasting serum
samples were used for the determination of concentrations
of glucose, creatinine, total cholesterol and its high density
fraction, triglycerides, and activity of alanine aminotransfer-
ase enzyme. Determination of urinary albumin and creati-
nine concentrations were done in the urine sample.
Biochemical analysis was conducted on the Olympus
AU400 clinical chemistry analyzer (Beckman Coulter Inc,
Brea CA, USA). Calculations of serum low density lipopro-
tein fraction using Friedwald’s formula and urinary albu-
min to creatinine ratio (ACR) were done.30,31 Whole
blood percent glycated hemoglobin (HbA1c) value was
determined using an ion exchange column chromatographic
technique (Biosystems SA, Barcelona, Spain) according to
the manufacturer’s instructions.
3.2.2. Genomic analysis
Whole EDTA blood was used for genomic DNA extraction
from peripheral mononuclear cells using a GeneJET columnbased genomic DNA puriﬁcation kit (Fermentas, Thermo
Fischer Scientiﬁc Inc., USA) according to the manufacturer’s
instructions. The integrity of the extracted DNA was assessed
qualitatively by electrophoresis on a 1% agarose gel. Quantita-
tive determination of concentration and purity of DNA was
done using the NanoDrop 1000 Spectrophotometer (Thermo
Fischer Scientiﬁc, Wilmington, Delaware USA).
The A313G SNP of the GSTP1 gene was determined using
a PCR – restriction fragment length polymorphism (RFLP)
according to the method described by Harries LW et al.
(1997).32 Brieﬂy, 12 lL (50–150 ng) of genomic DNA were
mixed in a 0.2 mL sterile eppendorf tube with 0.2 lL of each
forward (50-ACCCCAGGGCTCTATGGGAA-30) and reverse
(50-TGAGGGCACAAGAAGCCCCT-30) primers (Fermentas –
Thermo Fischer Scientiﬁc Inc., USA) in concentrations of
5 pmol per reaction tube, 12.5 lL DreamTaq Green PCR
Master Mix (2·) (Fermentas – Thermo Fischer Scientiﬁc
Inc., USA), and completed to a ﬁnal reaction volume of
25 lL using nuclease free sterile water. The PCR thermal
cycler (Quanta Biotech, UK) conditions were as follows; a
5 min initial denaturation phase at 95 C, followed by 30 cycles
of denaturation (94 C, 30 s), annealing (55 C, 30 s), and
extension (72 C, 30 s), and a ﬁnal elongation step of 5 min
at 72 C. The resulting 176-bp fragment, generated by PCR,
was electrophoretically separated on a 2% agarose gel and
visualized by ethidium bromide staining to conﬁrm its pres-
ence. The PCR product was subjected to an RFLP using an
Alw261 restriction endonuclease (Fermentas – Thermo Fischer
Scientiﬁc Inc., USA). The digestion reaction was carried out in
a 1.5 mL sterile eppendorf tube, where 5 lL of PCR product
were mixed with 0.5 lL enzyme, 1 lL enzyme buffer, and com-
pleted to a ﬁnal reaction volume of 15 lL with nuclease free
sterile water. The mixture was incubated at 37 C for one hour
using a thermomixer (Eppendorf AG Hamburg, Germany).
The digestion products electrophoretically separated on a
2% agarose gel revealed one of three possibilities; a single
undigested band at 176 base pairs indicating the presence of
a homozygote AA allele (wild type), the presence of a restric-
tion site resulting in two fragments (91 and 85 base pairs) indi-
cating the presence of a GG homozygote mutant allele, and
lastly three bands (176, 91 and 85 base pairs) indicating the
presence of an A/G heterozygote mutant allele.
Screening for deletions in the GSTM1 and GSTT1 genes
was done using PCR according to the method described by
Bid HK et al. (2010) for both genes.23 Brieﬂy, 12 lL of geno-
mic DNA (50–150 ng) was mixed in a 0.2 mL sterile eppren-
dorf tube with 0.2 lL of forward and reverse primers
(Fermentas – Thermo Fischer Scientiﬁc Inc., USA) in concen-
trations of 5 pmol per reaction tube, 12.5 lL DreamTaq
Green PCR Master Mix (2·) (Fermentas – Thermo Fischer
Scientiﬁc Inc., USA), and completed to a ﬁnal reaction volume
of 25 lL using nuclease free sterile water. An internal control
was used with every reaction in a multiplex manner to verify
the successfulness of PCR composed of forward and reverse
primers that amplify exon-7 of the CYP1A1 gene. Details of
primer sequences and thermocycler (S96 Quanta Biotech,
UK) conditions are available in Table 1. The PCR products
were visualized using electrophoretic separation on a 2% aga-
rose gel. PCR products representing GSTM1 and GSTT1 posi-
tive genotypes yielded bands of 215 and 480 bp, respectively,
while the internal positive control (CYP1A1) PCR product
band corresponded to 312 bp. Such genotyping approach did
Table 1 Primer sequences and cycler conditions for ampliﬁcation of GSTM1 and GSTT1 genes.
Genes Primers Cycler conditions
GSTM1 Forward GSTM1 Initial Denaturation 95 C–5 min
50-GAACTCCCTGAAAAGCTAAAGC-30 35 Cycles Denaturation 94 C–30 s
Reverse Annealing 55 C–30 s
50-GTTGGGCTCAAATATACGGTGG-30 Extension 72 C–30 s
Final elongation 72 C–10 min
GSTT1 Forward GSTT1 Initial Denaturation 94 C–5 min
50-TTCCTTACTGGTCCTCACATCTC-30 35 Cycles Denaturation 94 C–1 min
Reverse Annealing 59 C–1 min
50-TCACGGGATCATGGCCAGCA-30 Extension 72 C–1 min
Final elongation 72 C–10 min
CYP1A1 Forward
(Exon-7) 50-GAACTGCCACTTCAGCTGTCT-30
Reverse
50-CAGCTGCATTTGGAAGTGCTC-30
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GSTT1 deletion; hence, the GSTM1-0 or GSTT1-0 genotype
group included only patients homozygous for GSTM1 or GSTT1
deletion. The GSTM1-1 or GSTT1-1 genotype group included
homozygous and heterozygous carriers of the functional allele.
3.3. Statistical analysis
Statistical analysis of data was performed using statistical pack-
ages of Social Science (SPSS) version 20 (SPSS, Inc., Chicago,
IL,USA).33Datawere coded and fed to the SPSS software pack-
age.D’Agostino–PearsonK-squared test for normalitywas used
to test for the degree of deviation from normal distribution
across all quantitative variables in all groups and subgroups.
For normally distributed variables, descriptivemeasures namely
mean and standard deviation were applied and independent
samples t-test for comparison between groups. For abnormally
distributed quantitative variables, descriptive measures namely
median, and range were applied, and Mann–Whitney test for
comparison between groups. For comparing nominal clinical
data variables between groups, Chi-square test with a Monte
Carlo estimate of exact p-values as well as Fisher’s exact test
were used depending on the expected frequencies. Being a case
control study, Odds ratio was used to measure the impact of
GST genotypes or alleles on the risk of developing type 2 diabe-
tes mellitus. Chi-square test for goodness of ﬁt was used to com-
pare the observed frequencies of different GSTP1 genotypes
among all subjects to expected frequencies according to
Hardy–Weinberg equilibrium equation.34 A p-value less than
0.05 was considered statistically signiﬁcant.
4. Results
A total number of 105 individuals (54 T2DM patients and 51
healthy volunteers) were genotyped for the three members of
the GST family. Screening for the GSTT1, M1 and P1 gene
polymorphisms was done using multiplex PCR for the ﬁrst 2
isoenzymes and PCR-RFLP for the third one. The demo-
graphical characteristics, namely age and sex, are summarized
in Table 2. The duration of disease in all diabetic cases varied
from ﬁve to ﬁfteen years. A signiﬁcantly higher BMI mean
value was demonstrated in all diabetic cases compared to the
control group (Table 2). Atherosclerosis in diabetics was evi-denced by a signiﬁcantly higher median value of CIMT com-
pared to the control group (Table 2). Also median values of
both systolic and diastolic blood pressure were signiﬁcantly
higher in diabetic cases with vascular complications compared
to those without vascular complications and control group
(Table 2).
Poor glycemic control noted in diabetic cases was evidenced
by the signiﬁcantly higher mean values of whole blood glycat-
ed hemoglobin, and serum fasting glucose compared to the
control group. Renal affection in cases suffering from diabetic
nephropathy was noted by the signiﬁcantly higher median
value of urinary albumin to creatinine ratio in diabetics with
vascular complications compared to those without vascular
complications and control group (Table 2). The hypertensive
state present in diabetics with vascular complications could
be an aggravating factor. Furthermore the disturbed lipid pat-
tern secondary to poor glycemic control was also noted in dia-
betic cases (Table 2).
As regards the GSTs gene polymorphisms, the GSTP1
genotypes in controls and diabetic cases as well as the total
subjects were in agreement with Hardy Weinberg equilibrium
(Table 3). No signiﬁcant differences were noted between dia-
betic patients with and without vascular complications and
control group regarding GSTM1 and GSTT1 both inserted
and deleted (p= 0.631 and p= 0.832, respectively) (Table 4).
The only difference noted was in the GSTP1 SNP where dia-
betic cases had a lower wild genotype (AA) and a higher het-
erozygous (AG) genotype compared to control group with p-
value approaching statistical signiﬁcance (p= 0.053) (Table 4).
Furthermore, in cases with vascular complications the GSTP1
wild (AA) genotype was signiﬁcantly lower and the heterozy-
gous (AG) genotype was signiﬁcantly higher compared to
cases without vascular complications and control group
(p= 0.023) (Table 4). When diabetic cases with vascular com-
plications were categorized according to the type of vascular
complications, we came across a signiﬁcantly higher frequency
of GSTT1 gene insertion in cases presenting with retinopathy
and neuropathy (p= 0.034 and p= 0.019, respectively)
(Table 5). No statistically signiﬁcant differences were noted
in the frequencies of GSTM1, GSTT1 and GSTP1 gene poly-
morphisms when diabetic cases were categorized according to
the presence of one or more of vascular complications of dia-
betes (Table 6).
Table 2 Some demographical and clinical characteristics, anthropometric and radiological data, as well as biochemical parameters
among the studied groups.
Items Controls (n= 51)
mean/median ± SD/Min–Max
Diabetic patients(n= 54)
mean/median ± SD/Min–Max
p-value
Gender
Male n= 16 (31.4%) n= 20 (37.0%) v2p= 0.541
Female n= 35 (68.6%) n= 34 (63.0%)
Age (years) 43.37 ± 11.07 49.96 ± 8.99 tp1 = 0.001*
BMI (kg/m2) 27.39 ± 2.8 30.56 ± 3.97 tp1 < 0.001*
CIMT (cm) 0.44 (0.3–0.62) 0.58 (0.40–2.30) MWp1 < 0.001*
Duration of disease (years) – 10.5 ± 5.49 –
Whole blood HbA1c (%) 4.84 ± 0.38 8.52 ± 2.25
tp1 < 0.001*
Serum (Fasting)
Glucose (mg/dL) 90 (74–99) 168 (78–448) MWp1 < 0.001*
Creatinine (mg/dL) 0.9 (0.6–1.2) 1.0 (0.7–5.1) MWp1 < 0.001*
ALT (U/L) 15 ± 7 26 ± 12 tp1 < 0.001*
Total cholesterol (mg/dL) 174 ± 22 207 ± 12 tp1 < 0.001*
HDL-cholesterol (mg/dL) 55 ± 12 44 ± 13 tp1 < 0.001*
LDL-cholesterol (mg/dL) 100 ± 19 130 ± 45 tp1 < 0.001*
Triglycerides (mg/dL) 94 ± 31 172 ± 77 tp1 < 0.001*
Items Control group(n= 51) T2DM without vascular
complications(n= 27)
T2DM with vascular
complications(n= 27)
p2/p3/p4 values
Blood pressure
Systolic (mmHg) 115 (90–135) 130 (90–135) 140 (110–180) tp2 < 0.001*
tp3 < 0.001*
Diastolic (mmHg) 70 (60–85) 80 (60–85) 90 (60–110) tp4 < 0.001*
Urine ACR
(mg/gm) 11.0(2.0–28.5) 15.7 (2.3–29.6) 60.0 (1.5–1749.0) t p2 = 0.153
tp3 < 0.001*
tp4 < 0.001*
p1-value describes the statistical difference between control group and whole diabetic cases.
p2-value describes the statistical difference in urinary ACR between control group and diabetic cases without vascular complications.
p3-value describes the statistical difference in urinary ACR between control group and diabetic cases with vascular complications.
p4-value describes the statistical difference in urinary ACR between diabetic cases without and with vascular complications.
Abbreviations: ACR, Albumin to creatinine ratio; ALT, Alanine aminotransferase; BMI, body mass index; CIMT, Carotid intima media
thickness, HbA1c, Glycated hemoglobin, HDL-C, high density lipoprotein cholesterol, LDL-C, Low density lipoprotein cholesterol.
*A p-value less than 0.001 was considered highly signiﬁcant.
* A p-value less than 0.05 was considered statistically signiﬁcant.
Table 3 The agreement of GSTP1 genotypes with Hardy Weinberg (HW) equilibrium.
Genotype Observed HW expected x2 p-value
Number % Number %
Control group
Wild (AA) 38 74.5 37.1 72.7 1.002 0.316
Heterozygous mutant (AG) 11 21.6 12.8 25.1
Homozygous mutant (GG) 2 3.9 1.1 2.2
Diabetic group
Wild (AA) 29 53.7 30.4 56.3 0.995 0.318
Heterozygous mutant (AG) 23 42.6 20.3 37.6
Homozygous mutant (GG) 2 3.7 3.4 6.1
Total subjects
Wild (AA) 67 63.8 67.2 64.0 0.014 0.902
Heterozygous mutant (AG) 34 32.4 33.6 32.0
Homozygous mutant (GG) 4 3.8 4.2 4.0
A p-value less than 0.05 was considered statistically signiﬁcant.
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Table 5 Frequency of diabetic patients with the three GST gene polymorphisms according to each vascular complication.
Diabetic complications GSTM1 GSTT1 GSTP1 p-value
Present Deleted Present Deleted Wild type Heterozygous
No. % No. % No. % No. % No. % No. %
CAD v2p1 = 0.082
v2p2 = 0.581
v2p3 = 1.000
Positive 5 35.7 9 69.2 9 56.3 5 45.5 9 50.0 5 55.6
Negative 9 64.3 4 30.8 7 43.8 6 54.5 9 50.0 4 44.4
PAD FEp1 = 1.000
Positive 3 21.4 2 15.4 5 31.3 0 0.0 3 16.7 2 22.2 FEp2 = 0.060
Negative 11 78.6 11 84.6 11 68.6 11 100.0 15 83.3 7 77.8 FEp3 = 1.000
CVD
Positive
Negative
–
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
14 100.0 13 100.0 16 100.0 11 100.0 18 100.0 9 100.0
Retinopathy
Positive
Negative
v2p1 = 0.568
v2p2 = 0.034*
v2p3 = 0.695
8 57.1 6 46.2 5 68.8 3 27.3 10 55.6 4 44.4
6 42.9 7 53.8 11 31.3 8 72.7 8 44.4 5 55.6
Neuropathy
Positive
Negative
FEp1 = 0.326
FEp2 = 0.019*
FEp3 = 0.093
13 92.9 10 76.9 0 100.0 7 63.6 17 94.4 6 66.7
1 7.1 3 23.1 16 0.0 4 36.4 1 5.6 3 33.3
Nephropathy
Positive
Negative
FEp1 = 0.695
FEp2 = 0.692
FEp3 = 0.193
10 71.4 8 61.5 10 62.5 8 72.7 10 55.6 8 88.9
4 28.6 5 38.5 6 37.5 3 27.3 8 44.4 1 11.1
P1: statistical differences of GSTM1according to each vascular complication.
P2: statistical differences of GSTT1 according to each vascular complication.
P3: statistical differences of GSTP1 according to each vascular complication.
Abbreviations: CAD, Coronary artery disease; v2, Chi square test; FE, Fisher Exact test; PAD, peripheral arterial disease; CVD, cerebrovascular
disease.
* A p-value less than 0.05 was considered statistically signiﬁcant.
Table 4 Distribution of GSTM1, GSTT1, and GSTP1 gene polymorphisms among the studied groups.
GSTs genepolymorphisms Control group
(n= 51)
Total number of
diabetic cases (n= 54)
Diabetic cases with
vascular complications (n= 27)
Diabetic cases
without vascular
complications (n= 27)
p-value
Number % Number % Number % Number %
GSTM1 gene v2p1 = 0.631
v2p2 = 0.859Present 25 49.0 29 53.7 14 51.9 15 55.6
Deleted 26 51.0 25 46.3 13 48.1 12 44.4
GSTT1 gene v2p1 = 0.832
v2p2 = 0.507Present 33 64.7 36 66.7 16 59.3 20 74.1
Deleted 18 35.3 18 33.3 11 40.7 7 25.9
GSTP1 gene MCp1 = 0.053
MCp2 = 0.023*Wild (AA) 38 74.5 29 53.7 18 66.7 11 40.7
Heterozygous mutant (AG) 11 21.6 23 42.6 9 33.3 14 51.9
Homozygous mutant (GG) 2 3.9 2 3.7 0 0 2 7.4
p1: Statistical differences between control group and total number of diabetic cases.
p2: Statistical difference between control and each of diabetic cases with and without vascular complications of T2DM.
Abbreviations: MC, Monte Carlo test; v2, Chi square test.
* A p-value less than 0.05 was considered statistically signiﬁcant.
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ferent combinations of genotypes from the GST genes in both
control and diabetic cases could be involved in the risk of
T2DM development. Our study revealed a signiﬁcantly higher
frequency of combined heterozygous (AG) GSTP1 and null
GSTM1 genotypes among diabetic cases (Odds ratio = 6.285,
95% conﬁdence interval = 1.184–33.347, p= 0.021) (Table 7).In diabetic cases with and without vascular complica-
tions as well as in the whole group of diabetic cases, no
signiﬁcant associations were noted between the frequencies
of GST-M1, -T1 and -P1 gene polymorphisms and each
of glycated hemoglobin, fasting serum levels of glucose, tri-
glycerides, total cholesterol, and high and low density lipo-
protein fractions of cholesterol (Our unpublished results).
Table 6 The frequency of diabetic patients with GSTM1, GSTT1, and GSTP1 gene polymorphisms according to the presence of one
or more vascular complications of diabetes.
GSTs gene polymorphisms Number of diabetic microvascular and macrovascular complications p-value
1 2 3 4 5
No. % No. % No. % No. % No. %
GSTM1
Present 3 21.4 3 21.4 3 21.4 4 28.6 1 7.1 0.921
Deleted 4 30.8 1 7.7 4 30.8 3 23.1 1 7.1
GSTT1
Present 2 12.5 3 18.8 3 18.8 6 37.5 2 12.5 0.132
Deleted 5 45.5 1 9.1 4 36.4 1 9.1 0 0.0
GSTP1
A allele 11 78.6 7 87.5 12 85.7 13 92.9 2 50.0 0.393
G allele 3 21.4 1 12.5 2 14.3 1 7.1 2 50.0
A p-value less than 0.05 was considered statistically signiﬁcant.
Monte Carlo test was used for comparing between numbers of complications categories.
Table 7 Distribution of combinations of glutathione S-transferase genotypes among diabetic patients and control group and the risk
of developing diabetes mellitus.
Combined GST polymorphisms Control group (n= 51) Diabetic patients (n= 54) p-value OR 95% Conﬁdence interval
No. % No. %
GSTM1 and GSTT1
Both present  16 31.4 22 40.7
Both deleted 26 51.0 21 38.9 v2p= 0.226 0.587 0.247–1.392
One present + one deleted 9 17.6 11 20.4 v2p= 0.832 0.889 0.298–2.647
GSTM1 and GSTP1
Present M1 + wild (AA) P1  16 31.4 14 25.9
Present M1 + hetero mutant (AG) P1 9 17.6 12 22.2 v2p= 0.461 1.523 0.495–4.685
Present M1 + homo mutant (GG) P1 0 0 2 3.7 FEp= 0.484 - -
Deleted M1 + wild (AA) P1 22 43.1 15 27.8 v2p= 0.615 0.779 0.294–2.060
Deleted M1 + hetero mutant (AG) P1 2 3.9 11 20.4 v2p= 0.021* 6.285 1.184–33.347
Deleted M1 + homo mutant (GG) P1 2 3.9 0 0.0 FEp= 0.492 - -
Present M1 + AG and GG-P1 9 17.6 14 25.9 v2p= 0.305 1.778 0.590–5.354
Deleted M1 + AG and GG- P1 4 7.8 11 20.4 v2p= 0.090 3.142 0.814–12.131
GSTT1 and GSTP1
Present T1 + wild (AA) P1  24 47.1 23 42.6
Present T1 + hetero mutant (AG) P1 7 13.7 11 20.4 v2p= 0.379 1.639 0.542–4.960
Present T1 + homo mutant (GG) P1 1 2.0 2 3.7 FEp= 0.552 2.087 0.176–24.616
Deleted T1 +Wild (AA) P1 14 27.5 6 11.1 FEp= 0.152 0.447 0.146–1.362
Deleted T1 + hetero mutant (AG) P1 4 7.8 12 22.2 v2p= 0.070 3.130 0.881–11.123
Deleted T1 + homo mutant (GG) P1 1 2.0 0 0.0 FEp= 1.000 -
Present T1 + AG and GG-P1 5 15.7 13 24.1 v2p= 0.091 2.713 0.834–8.823
Deleted T1 + AG an GG- P1 5 9.8 12 22.2 v2p= 0.124 2.504 0.762–8.230
Abbreviations: FE, Fisher exact test; OR, Odds ratio; , reference group; v2: Chi square test; Hetero, heterozygous; Homo, homozygous.
* A p-value less than 0.05 was considered statistically signiﬁcant.
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A number of epidemiological studies have tested possible
associations between polymorphisms of the GST isoforms
particularly deletions in the GSTM1 and GSTT1 genes (null
genotypes) and the GSTP1 A313G SNP with disease risk or
therapy outcome in different types of pathologies.3,35–37
Several population-based studies have reported a GSTM1
prevalence ranging from 16% to 60%.38 Asians and Cauca-
sians have the highest frequencies (50–53%) while black popu-
lations including Africans, African–American and black
populations of Brazil have the lowest ones.39–41 This was inagreement with our result as 51% of controls showed GSTM1
deletion which was also close to the respective frequencies
reported for Middle East Arabs41 and Egyptians42 with fre-
quencies in the range of Caucasian healthy populations. Such
ﬁnding may be explained by the fact that Egyptians belong to
the Mediterranean Caucasian race. No signiﬁcant difference
was noted in the frequency of GSTM1 null genotype polymor-
phism between diabetic patient group and control group
(Table 4). Such ﬁnding is in agreement with results reported
by some studies20–22 whereas other studies showed a signiﬁcant
association between the frequency of GSTM1 genotype and
T2DM.3,22–24
80 M.A. Zaki et al.As regards the GSTT1 polymorphism among controls in
our study, we demonstrated a frequency rate of GSTT1 null
genotype (35.3%) that did not vary too much from European
and Mediterranean that ranged from 10.4% to 42.5%38, being
the highest among Chinese (64%), followed by Koreans
(60%), African–Americans (22%), Caucasians (29%) and
Asian–Indians (16%), and the lowest among Mexican–Ameri-
cans (10%).43 When considering gender differences in the
GSTT1 genotype among our control group, the female
(68.6%) to male ratio (31.4%) was high which might explain
the higher frequency of GSTT1 deletion among female con-
trols. A meta-analysis study did report a signiﬁcantly higher
frequency of GSTT1 deletion among healthy Caucasian
females, yet was not able to explain it on biological grounds,
since GSTT1 gene is not located on the sex chromosome.38
The GSTT1 null genotype polymorphism did not show any
signiﬁcant association with T2DM in our study (v2p= 0.832)
since it did not show any signiﬁcant difference between control
group and diabetic cases (Table 4). This was in agreement with
some studies.21–24 The results of our study are opposed to
Egyptian,3 Chinese19 and Brazilian20 researchers who not only
observed lack of association between GSTM1 genotypes and
T2DM, but also observed that the prevalence of GSTT1-null
genotype is a more critical risk factor in T2DM development.
In South India, Ramprasath T et al. (2011)26 in their study on
South Indian T2DM patients observed signiﬁcant associations
between T2DM and both null genotypes of GSTM1 and
GSTT1. Amer et al.3 also indicated that the GSTM1 and
GSTT1 genotype distributions signiﬁcantly differ between
T2DM patients and controls in Egypt. In addition, they
reported that the combined genotype of GSTM1-null/
GSTT1-null may increase the risk of T2DM development.
The present study did not relate the risk of developing dia-
betic vascular complications to the presence of the null geno-
type polymorphisms in the GSTM1 or GSTT1 genes
(Table 5). On the contrary, the GSTT1 null genotype polymor-
phism showed a signiﬁcantly decreased frequency in those suf-
fering from neuropathy and retinopathy (Table 5). Cilensˇek I
et al. (2012)44 proposed a protective effect for GSTM1 null
genotype against retinopathy explained by an up-regulation
of other antioxidant enzymes such as manganese superoxide
dismutase which become more effective in detoxiﬁcation of
atherogenic compounds. Our explanation for a protective
effect of GSTT1 null genotype could rely on the same reason.
The high activity of cytochrome P450 system in such patients
might offer another explanation.45 However, it should be
stressed that to date no ﬁrm evidence exists that such mecha-
nisms promote efﬁcient defense against the development and
progression of T2DM vascular complications. Hence, addi-
tional research is mandatory in this area.44,45
As regards the GSTP1 gene polymorphism in the present
study, the genotype distributions among controls, diabetics
and total subjects were in agreement with the Hardy–Weinberg
equilibrium (Table 3). Such genotype distribution was in agree-
ment with other studies concerning GSTP1 genotype distribu-
tion among Egyptians.28,46 Contrary to studies that did not
report an association of GSTP1 (A313G) SNP with
T2DM,21,22,24 our study was able to demonstrate a statistical
difference that approached the level of signiﬁcance in the fre-
quencies of GSTP1 genotypes between whole diabetic patient
group and control group, with a lower frequency of wild
(AA) genotype and a higher frequency of heterozygous (AG)mutant genotype demonstrated in all diabetic cases
(MCp= 0.053). Such a statistical difference became signiﬁcant
when diabetic cases divided according to the presence or
absence of vascular complications were compared to the con-
trol group (p= 0.023) (Table 4). This ﬁnding is in agreement
with results of Bid HK et al. (2010)23 in North Indian
T2DM cases and Amer MA et al. (2012)28 in Egyptian
T2DM cases, implicating the GSTP1 gene polymorphism in
the susceptibility to and risk of T2DM development among
Egyptians. The domination of the G allele in the GSTP1 poly-
morphism (A313G) results in reduction of GSTP1 enzyme
activity. Consequently, the cell becomes more susceptible to
mutation and damage from exposure to electrophiles and
ROS.47
Despite the signiﬁcance noted in the G allele in GSTP1 gene
polymorphism among diabetic cases, our study failed to dem-
onstrate any signiﬁcant association between GSTP1 polymor-
phism and any of diabetic vascular complications (Table 5)
which is not far from the result reported by Townsend D
et al. (2003).48 Furthermore, no signiﬁcant associations were
found between GSTM1, GSTT1 and GSTP1 gene polymor-
phisms and the number of vascular complications in T2DM
cases presenting with them (Table 6).
When comparing the combined effect of the null genotypes
of GSTM1 and GSTT1 as well as the GSTP1 SNP and the risk
of developing T2DM, a signiﬁcantly higher frequency of com-
bined GSTP1 heterozygous (A/G) and GSTM1 deleted geno-
type in the whole diabetic group was demonstrated compared
to the control group (Odds ratio = 6.285, 95% conﬁdence
interval = 1.184–33.347, p= 0.021) (Table 7). This result
points out the value of investigating the combined effects of
genotypes in population studies that might be synergistically
associated with the risk of diseases.
The association studies that evaluate the impact of genotype
on disease progression are usually limited by the fact that the
duration of diabetes, together with the uncontrolled hypergly-
cemia and high BMI are the most important factors associated
with the development of diabetic vascular complications.45
Other factors involved in the hyperglycemia-induced cell dam-
age could inﬂuence our results. An important contributor in
that area is advanced glycation end products that modify
ROS formation through their corresponding receptors and
therefore inﬂuence the production of growth factors and cyto-
kines by affected cells.49 Our results thus represent only a part
of the complex pathological network of diabetes and its related
vascular complications.6. Conclusion
In conclusion, our study was only able to demonstrate an
increased risk of developing T2DM but not its vascular related
complications among cases having heterozygous (AG) GSTP1
A313G polymorphism alone as well as when combined with
GSTM1 null genotype. One of the limitations of this study
was the evaluation of selected polymorphisms that may not
be representative of the whole polymorphisms in the GST gene
cluster. Thus, functional studies are needed to clarify the exact
molecular mechanisms by which GST gene variants may exert
inﬂuence on pancreatic beta cells destruction. Furthermore
conducting a large-scale cohort study in Egyptian population
may conﬁrm the role of GSTM1, T1 and P1 gene polymor-
Gene polymorphisms and risk of type 2 diabetes mellitus 81phisms in the pathogenesis of T2DM and its related complica-
tions. Moreover, performing genetic studies concerning genes
involved in ROS elimination such as manganese activated
superoxide dismutase (MnSOD), catalase, and glutathione
reductase would be of value in exploring the genetic related
antioxidant defense system in T2DM.
Conﬂict of interest
None to declare by the authors of this manuscript.
References
1. American Diabetes Association. Diagnosis and classiﬁcation of
diabetes mellitus. Diabetes Care 2012;3:S64–71.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the
prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract
2010;87:4–14.
3. Amer MA, Ghattas MH, Abo-Elmatty DM, Abou-El-Ela SH.
Inﬂuence of glutathione S-transferase polymorphisms on type-2
diabetes mellitus risk. Genet Mol Res 2011;10:3722–30.
4. Pereira EC, Ferderbar S, Bertolami MC, Faludi AA, Monte O,
Xavier HT, et al. Biomarkers of oxidative stress and endothelial
dysfunction in glucose intolerance and diabetes mellitus. Clin
Biochem 2008;41:1454–60.
5. Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Santini SA,
Zuppi C, et al. Oxidative stress, nitric oxide, and diabetes. Rev
Diabet Stud 2010;7:15–25.
6. Irshad M, Chaudhuri PS. Oxidant-antioxidant system: role and
signiﬁcance in human body. Indian J Exp Biol 2002;40:1233–9.
7. Rolo AP, Palmeira CM. Diabetes and mitochondrial function:
Role of hyperglycemia and oxidative stress. Toxicol Appl Phar-
macol 2006;212:167–78.
8. Gallou G, Ruelland A, Legras B, Maugendre D, Allannic H,
Cloarec L. Plasma malondialdehyde in type 1 and type 2 diabetic
patients. Clin Chim Acta 1993;28(214):227–34.
9. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic
complications: a new perspective on an old paradigm. Diabetes
1999;48:1–9.
10. Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between
antioxidant enzyme gene expression and antioxidative defense
status of insulin-producing cells. Diabetes 1997;46:1733–42.
11. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases.
Annu Rev Pharmacol Toxicol 2005;45:51–88.
12. Dirr H, Reinemer P, Huber R. X-ray crystal structures of cytosolic
glutathione S-transferases. Implications for protein architecture,
substrate recognition and catalytic function. Eur J Biochem
1994;220:645–61.
13. Bresell A, Weinander R, Lundqvist G, Raza H, Shimoji M, Sun
TH, et al. Bioinformatic and enzymatic characterization of the
MAPEG superfamily. FEBS J 2005;272:1688–703.
14. Oakley A. Glutathione transferases: a structural perspective. Drug
Metab Rev 2011;43:138–51.
15. Wilce MC, Parker MW. Structure and function of glutathione S-
transferases. Biochim Biophys Acta 1994;1205:1–18.
16. Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary
differences in the expression of the human glutathione transferase
active on trans-stilbene oxide are due to a gene deletion. Proc Natl
Acad Sci USA 1988;85:7293–7.
17. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt
HM, et al. Human glutathione S-transferase theta (GSTT1):
cDNA cloning and the characterization of a genetic polymor-
phism. Biochem J 1994;300:271–6.
18. Zimniak P, Nanduri B, Pikula S, Bandorowicz-Pikula J, Singhal
SK, Srivastava SK, et al. Naturally occurring human glutathione
S-transferase GSTP1-1 isoforms with isoleucine and valine inposition 104 differ in enzymic properties. Eur J Biochem
1994;224:893–9.
19. Wang G, Zhang L, Li Q. Genetic polymorphisms of GSTT1,
GSTM1, and NQO1 genes and diabetes mellitus risk in Chinese
population. Biochem Biophys Res Commun 2006;341:310–3.
20. Pinheiro DS, Rocha Filho CR, Mundim CA, Ju´nior Pde M,
Ulhoa CJ, Reis AA, et al. Evaluation of glutathione S-transferase
(GSTM1 and GSTT1) deletion polymorphisms on type-2 diabetes
mellitus risk. PLoS One 2013;8:e76262.
21. Yalin S, Hatungil R, Tamer L, Ates NA, Dogruer N, Yildirim H,
et al. Glutathione S-transferase gene polymorphisms in Turkish
patients with diabetes mellitus. Cell Biochem Funct 2007;25:
509–13.
22. Go¨nu¨l N, Kadioglu E, Kocabas NA, Ozkaya M, Karakaya AE,
Karahalil B. The role of GSTM1, GSTT1, GSTP1, and OGG1
polymorphisms in type 2 diabetes mellitus risk: a case-control
study in a Turkish population. Gene 2012;505:121–7.
23. Bid HK, Konwar R, Saxena M, Chaudhari P, Agrawal CG,
Banerjee M, et al. Association of glutathione S-transferase
(GSTM1, T1 and P1) gene polymorphisms with type 2 diabetes
mellitus in north Indian population. J Postgrad Med 2010;56:
176–81.
24. Moasser E, Kazemi-Nezhad SR, Saadat M, Azarpira N. Study of
the association between glutathione S-transferase (GSTM1,
GSTT1, GSTP1) polymorphisms with type II diabetes mellitus
in southern of Iran. Mol Biol Rep 2012;39:10187–92.
25. Hori M, Oniki K, Ueda K, Goto S, Mihara S, Marubayashi T,
et al. Combined glutathione S-transferase T1 and M1 positive
genotypes afford protection against type 2 diabetes in Japanese.
Pharmacogenomics 2007;8:1307–14.
26. Ramprasath T, Murugan PS, Prabakaran AD, Gomathi P,
Rathinavel A, Selvam GS. Potential risk modiﬁcations of GSTT1,
GSTM1 and GSTP1 (glutathione S-transferases) variants and
their association to CAD in patients with type 2 diabetes. Biochem
Biophys Res Commun 2011;47:49–53.
27. Tang ST, Wang CJ, Tang HQ, Zhang Q, Wang Y. Evaluation of
glutathione S-transferase genetic variants affecting type 2 diabetes
susceptibility: a meta-analysis. Gene 2013;530:301–8.
28. Amer MA, Ghattas MH, Abo-Elmatty DM, Abou-El-Ela SH.
Evaluation of glutathione S-transferase P1 genetic variants
affecting type-2 diabetes susceptibility and glycemic control. Arch
Med Sci 2012;8:631–6.
29. Baldassarre D, Werba JP, Tremoli E, Poli A, Pazzucconi F, Sirtori
CR. Common carotid intima-media thickness measurement. A
method to improve accuracy and precision. Stroke
1994;25:1588–92.
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem
1972;18:499–502.
31. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the
albumin/creatinine ratio to detect microalbuminuria: implications
of sex and race. J Am Soc Nephrol 2002;13:1034–9.
32. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR.
Identiﬁcation of genetic polymorphisms at the glutathione S-
transferase Pi locus and association with susceptibility to
bladder, testicular and prostate cancer. Carcinogenesis
1997;18:641–4.
33. Puri BK. SPSS in practice: an illustrated guide. 2nd ed. London,
New York: Arnold; 2002.
34. Hardy GH. Mendelian proportions in a mixed population. Science
1908;28:49–50.
35. Tamer L, Calikog˘lu M, Ates NA, Yildirim H, Ercan B, Saritas E,
et al. Glutathione S-transferase gene polymorphisms (GSTT1,
GSTM1, GSTP1) as increased risk factors for asthma. Respirology
2004;9:493–8.
36. Moore LE, Huang WY, Chatterjee N, Gunter M, Chanock S,
Yeager M, et al. GSTM1, GSTT1, and GSTP1 polymorphisms
82 M.A. Zaki et al.and risk of advanced colorectal adenoma. Cancer Epidemiol
Biomarkers Prev 2005;14:1823–7.
37. Ozerkan K, Atalay MA, Yakut T, Doster Y, Yilmaz E, Karkucak
M. Polymorphisms of glutathione S-transferase M1, T1, and P1
genes in endometrial carcinoma. Eur J Gynaecol Oncol
2013;34:42–7.
38. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H,
Autrup JL, et al. Metabolic gene polymorphism frequencies in
control populations. Cancer Epidemiol Biomarkers Prev
2001;10:1239–48.
39. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF.
Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphism:
evidence of a lack of association in Caucasians and African
Americans. Cancer Res 1998;58:65–70.
40. Gattas GJF, Kato M, Soeres-vieira JA, Siraque MS, Kohler P,
Gomes L, et al. Ethnicity and glutathione S-transferase (GSTM1/
GSTT1) polymorphisms in a Brazilian population. Braz J Med
Biol Res 2004;37:451–8.
41. Bu R, Gutie´rrez MI, Al-Rasheed M, Belgaumi A, Bhatia K.
Variable drug metabolism genes in Arab population. Pharmacog-
enomics J 2004;4:260–6.
42. Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M,
Moursi N, et al. Genotype and allele frequencies of TPMT,
NAT2, GST, SULT1A1 and MDR1 in the Egyptian population.
Br J Clin Pharmacol 2003;55:560–9.43. Nelson HH, Wiencke JK, Christiani DC, Cheng TJ, Zuo ZF,
Schwartz BS. Ethnic differences in the prevalence of the homo-
zygous deleted genotype of glutathione S-transferase theta. Car-
cinogenesis 1995;16:1243–5.
44. Cilensˇek I, Mankocˇ S, Petrovicˇ MG, Petrovicˇ D. GSTT1 null
genotype is a risk factor for diabetic retinopathy in Caucasians
with type 2 diabetes, whereas GSTM1 null genotype might confer
protection against retinopathy. Dis Markers 2012;32:93–9.
45. Hovnik T, Dolzan V, Bratina NU, Podkrajsek KT, Battelino T.
Genetic polymorphisms in genes encoding antioxidant enzymes
are associated with diabetic retinopathy in type 1 diabetes.
Diabetes Care 2009;32:2258–62.
46. Ramzy MM, Solliman MM, Abdel-Haﬁz HA, Salah R. Genetic
polymorphism of GSTM1 and GSTP1 in lung cancer in Egypt. Int
J Collab Res Int Med Public Health (IJCRIMPH) 2011;3:41–51.
47. Grubisˇa I, Otasˇevic P, Despotovic N, Dedic V, Milasˇin J, Vucinic
N. Genetic polymorphism of glutathione S-transferase P1
(GSTP1) Ile105Val and susceptibility to atherogenesis in patients
with type 2 diabetes mellitus. Genetika 2013;45:227–36.
48. Townsend D, Tew K. Cancer drugs, genetic variation and the
Glutathione S-transferase gene family. Am J Pharmacogenomics
2003;3:157–72.
49. Brownlee M. The pathobiology of diabetic complications: a
unifying mechanism. Diabetes 2005;54:1615–25.
